Glucose Control Using Continuous Glucose Monitoring in People With Type 2 Diabetes Who Have Had Acute Myocardial Infarct

Type 2 Diabetes Clinical Trial

— GLAM  

Official title:

Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05431296
• Other study ID #: 21CX7252
• Status: Recruiting
• Phase: N/A
• Start date: February 7, 2023
• Est. completion date: February 2025

Study information

• Verified date: September 2023
• Source: Imperial College London
• Contact: Neil Hill, BMBS, PhD
• Phone: 02033111016
• Email: neil.hill[@]nhs.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Glucose monitoring after Acute Myocardial infarct in people with diabetes is a Dexcom funded study that is investigating whether the use of continuous glucose monitors (Dexcom ONE model) in people with type 2 diabetes facilitates time in glycaemic range in the 6 months after an acute myocardial infarction. As an exploratory outcome it will investigate whether time in glycaemic range is associated with changes in mortality and major adverse cardiac events in the 6 months after acute myocardial infarct.

Description:

The study

1. Patients recruited from cardiology services after ACS (n=140 participants)

Following informed consent study participants with known diabetes who have had an acute myocardial infarct will be recruited. Participants will be randomly allocated to either the intervention group, referred to as cohort 'a', or to the control group, referred to cohort 'b'. They will be randomised using permuted blocks in a 5:2 ratio (intervention:control). CGM (real-time or blinded) will be applied to participants prior to discharge.

Following hospital discharge, we will evaluate the effects of changes in blood glucose levels on cardiac and health outcomes. Participants recruited to cohort 'a' will wear real-time CGM continuously after hospital discharge for 26 weeks. They will have face-to-face, telephone or video reviews of CGM data at 4 and 12 weeks with clinician-led diabetes treatment escalation according to NICE guidelines based aiming for >70% time in target blood glucose range, 3.9-10mmol/L (50% for older or high risk individuals). Participants recruited to cohort 'b' will wear blinded CGM for 10 days after insertion. They will wear blinded CGM again for 10 days , with the second sensor insertion at days 17-23, third sensor insertion during week 10 and fourth sensor insertion during week 24. Following each sensor wear, participants in cohort 'b' will have a study visit when their sensor data will be downloaded. Participants in cohort 'b' will receive face-to-face or remote support to insert and establish blinded CGM but no clinical review and the participant should manage their diabetes as the participant normally would. At 26 weeks data will be analysed for all primary and secondary outcomes.

The participants who receive real-time CGM will be compared to age and sex-matched controls, who's data will be obtained from the NIHR Cardiovascular Health Informatics Collaborative for comparison of cardiovascular outcomes.

At 26 weeks data (clinical details of hospital admissions, further cardiac events, medication changes, blood test results obtained from hospital records and on discussion with the participant) will be collected for all primary and secondary outcomes. Imperial College Healthcare NHS Trust uses an electronic patient record system that is connected to the central NHS Spine and is updated in real-time. People who have died, even if the person has died out of hospital, will be recorded as deceased and this will be visible to the research team. End of study will be defined as Last Subject Last Visit (LSLV) at which point the participant will be asked to return or post back their study equipment and the participant will revert to standard care with their usual GP, community or hospital diabetes team.

Eligible participants admitted to the Hammersmith Hospital HAC with confirmed ACS will be recruited as soon as possible after hospital admission. Patients lacking capacity to consent will not be recruited. During admission, HbA1c levels will be sent as part of routine blood testing.

The research team will collect full medical and medication history, as well as historic bloods test results from the hospital computer systems as per routine clinical care. All participants recruited during their hospital admission will have blood tests (for HbA1c and other markers of metabolism) during admission and at 4, 12 and 24-26 weeks.

Participants in cohorts 'a' and 'b' will be asked to complete the Diabetes Treatment Satisfaction Scale questionnaire, the Audit of Diabetes Dependent Quality of Life questionnaire and the Hypoglycaemia Symptom Rating Questionnaire at the time of recruitment, and then at 4, 12, and 24 weeks. Participants will also be asked to fill out an Audit of Diabetes Dependent Quality of Life-19 questionnaire at the time of recruitment and at 12 and 24 weeks.

2. Patients recruited from diabetes and cardiology clinics after ACS (n=20 participants)

Eligible participants reviewed in clinic with confirmed previous ACS will be recruited. Patients lacking capacity to consent will not be recruited. HbA1c levels will be sent as part of routine blood testing. The research team will collect full medical and medication history, as well as historic bloods test results from the hospital computer systems as per routine clinical care.

Blinded CGM will be applied to 20 participants with a history of ACS more than 6 months ago, but less than 10 years ago and a known diagnosis of type 2 diabetes who take one or oral diabetic agents, and/or GLP 1 receptor analogue, and/or insulin. The blinded CGM will be worn for 10 days and then returned to (or collected by) the study team.

These participants be asked to complete a Diabetes Treatment Satisfaction Scale questionnaire, the Audit of Diabetes Dependent Quality of Life questionnaire and the Hypoglycaemia Symptom Rating Questionnaire at the time of recruitment. The participants will have a blood test looking at glycaemic control and markers of metabolism at the time of recruitment.

3. Data collection from the Health Information Collaborative

The participants who receive real-time CGM will be compared to age and sex-matched controls, who's data will be obtained from the NIHR Cardiovascular Health Informatics Collaborative for comparison of cardiovascular outcomes. Imperial College Healthcare NHS Trust has led the NIHR Cardiovascular Health Informatics Collaborative, which was established to enable the sharing and repurposing of routinely captured clinical data for re-use in research. Clinical patient data is extracted and put into a tabular format which includes demographics, emergency department attendance, inpatient episodes, blood tests, diagnoses, operations and procedures, echocardiography measurements and survival status. This infrastructure has been used to investigate patient outcomes in previous studies and will provide endpoint data for the patients enrolled into this study.

2. Clinical study recruitment: Single Centre- Imperial College Healthcare NHS Trust Design:

Randomised control trial

Population:

Interventional cohort: 100 participants with type 2 diabetes and acute myocardial infarction will wear real time CGM for 26 weeks Control: 40 participants with type 2 diabetes and acute myocardial infarction will wear blinded CGM for 10 days at 4 time points in the 6 months after infarct.

Clinic cohort: 20 participants with type 2 diabetes who have had a myocardial infarct > 6 months ago but <10 years ago will wear blinded CGM for 10 days.

Case control: NIHR Cardiovascular Health Informatics Collaborative dataset

Timescale: Each participant will be in the trial for 6 months. It is anticipated that it will take 18-24 months to recruit to target study number.

3. Statistics The study is powered to detect a change of between 7.2 and 13.2% difference in time in range glucose 3.9-10mmol/l between the real time and blinded CGM groups at 6 months depending the standard deviation used in the power calculation with two tailed alpha of 0.05 and power of 80%. This difference is thought to be a clinically meaningful and achievable difference.

For each questionnaire, mean ± SD values or percentiles appropriate to the distribution will be given by randomization group for the total score and each subscale. Treatment group comparisons will be made using linear models.

The following tabulations will be performed according to treatment group without statistical testing: baseline demographics and clinical characteristics, protocol deviations, device malfunctions and other reported device issue.

For all CGM outcomes, a multilevel model of repeated measures (MMRM) will be used.

4. Data During the course of the study visits some data will be stored on laptop computers, not connected to the Internet, for later statistical analysis. These data will be coded and non- identifiable. Laptop computers may be used during the visits for portability and convenience. At the end of each visit the anonymised data will be transferred immediately to a secure web-server (details below) and will be deleted from the laptop.

Any identifiable participant data will be stored in a locked filing cabinet in a secure room in each investigation centre. Only clinical research team will have access to this participant identifiable data.

5. Adverse Events (AEs) Reporting Procedures. All adverse events will be reported. Depending on the nature of the event the reporting procedures below will be followed. Any questions concerning adverse event reporting will be directed to the Chief Investigator in the first instance.

Non serious AEs: All such events will be recorded. Serious Adverse Events (SAEs): An SAE form will be completed and faxed to the Chief Investigator within 24 hours. However, hospitalisations for elective treatment of a pre-existing condition do not need reporting as SAEs.

Reports of related and unexpected SAEs will be submitted within 15 days of the Chief Investigator becoming aware of the event. The Chief Investigator will also notify the Sponsor of all SAEs, where in the opinion of the Chief Investigator, the event is:

'related', i.e. resulted from the administration of any of the research procedures; and 'unexpected', i.e. an event that is not listed in the protocol as an expected occurrence Local investigators will report any SAEs as required by their Local Research Ethics Committee, Sponsor and/or Research & Development Office.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: February 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

From the Hammersmith Hospital In-patient Cardiology Services:

• Adults aged >18 years

• Known or newly diagnosed type 2 diabetes

• Taking one or more oral hypoglycaemic agent, GLP1 receptor analogue and/or insulin

• Admitted to Hammersmith Hospital cardiology inpatient services with ACS

• Raised blood troponin level on admission

From Imperial College Healthcare Trust Diabetes and Cardiology Clinics:

• Adults aged >18 years

• Known type 2 diabetes

• Previous acute coronary syndrome within the last 10 years but > 6 months ago

• Taking one or more oral hypoglycaemic agent and /or GLP1 receptor analogue, and/or insulin

Exclusion Criteria:

From the Hammersmith Hospital In-patient Cardiology Services:

• HbA1c <48mmol/mol

• People who have previously had bariatric surgery

• People taking hydroxyurea

• People who undergo haemodialysis or peritoneal dialysis

• Unable to participate due to other factors, as assessed by the Chief Investigators

• Pregnancy as determined by clinical team

• Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year

From Imperial College Healthcare Trust Diabetes and Cardiology Clinics:

• HbA1c <48mmol/mol

• People who have previously had bariatric surgery

• People taking hydroxyurea

• People who undergo haemodialysis or peritoneal dialysis

• Unable to participate due to other factors, as assessed by the Chief Investigators

• Pregnancy as determined by clinical team

• Known to have a terminal condition or conditions that suggest a life expectancy less than 1 year

• Previous acute coronary syndrome more than 10 years ago or within the last 6 months

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Acute Myocardial Infarction With ST Elevation
• Diabetes Complications
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Infarction
• Myocardial Infarction
• ST Elevation Myocardial Infarction
• Type 2 Diabetes

Intervention

Device:
• Dexcom ONE Continuous Glucose Monitoring System
The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.

Locations

Country	Name	City	State
United Kingdom	Hammersmith Hospital inpatient cardiology services	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

References & Publications (11)

Bauters C, Lemesle G, de Groote P, Lamblin N. A systematic review and meta-regression of temporal trends in the excess mortality associated with diabetes mellitus after myocardial infarction. Int J Cardiol. 2016 Aug 15;217:109-21. doi: 10.1016/j.ijcard.2016.04.182. Epub 2016 May 4. — View Citation

Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006 Apr;29(4):765-70. doi: 10.2337/diacare.29.04.06.dc05-1894. — View Citation

Jackson MA, Ahmann A, Shah VN. Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring. Diabetes Technol Ther. 2021 Mar;23(S1):S27-S34. doi: 10.1089/dia.2021.0007. — View Citation

Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. JAMA. 2021 Jun 8;325(22):2273-2284. doi: 10.1001/jama.2021.6530. — View Citation

Lee W, Kim SH, Yoon CH, Suh JW, Cho YS, Youn TJ, Chae IH. Impact of Long-term Glycosylated Hemoglobin in Patients with Acute Myocardial Infarction: a retrospective cohort study. Sci Rep. 2020 Apr 21;10(1):6726. doi: 10.1038/s41598-020-63802-1. — View Citation

Li M, Chen G, Feng Y, He X. Stress Induced Hyperglycemia in the Context of Acute Coronary Syndrome: Definitions, Interventions, and Underlying Mechanisms. Front Cardiovasc Med. 2021 May 12;8:676892. doi: 10.3389/fcvm.2021.676892. eCollection 2021. — View Citation

Lu J, Wang C, Shen Y, Chen L, Zhang L, Cai J, Lu W, Zhu W, Hu G, Xia T, Zhou J. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care. 2021 Feb;44(2):549-555. doi: 10.2337/dc20-1862. Epub 2020 Oct 23. — View Citation

Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995 Jul;26(1):57-65. doi: 10.1016/0735-1097(95)00126-k. — View Citation

Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res. 1997 Apr;34(1):248-53. doi: 10.1016/s0008-6363(96)00263-5. Erratum In: Cariovasc Res 1997 Dec;36(3):460. — View Citation

Oser TK, Litchman ML, Allen NA, Kwan BM, Fisher L, Jortberg BT, Polonsky WH, Oser SM. Personal Continuous Glucose Monitoring Use Among Adults with Type 2 Diabetes: Clinical Efficacy and Economic Impacts. Curr Diab Rep. 2021 Dec 9;21(11):49. doi: 10.1007/s11892-021-01408-1. — View Citation

Yapanis M, James S, Craig ME, O'Neal D, Ekinci EI. Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring. J Clin Endocrinol Metab. 2022 May 17;107(6):e2221-e2236. doi: 10.1210/clinem/dgac034. — View Citation

* Note: There are 11 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	MACE endpoint defined as death due to cardiac cause or hospitalisation with acute coronary syndrome (including MI and unstable angina); heart failure; unscheduled revascularisation; arrhythmia; cerebrovascular event	Exploratory outcome	26 weeks
Other	All cause mortality	Exploratory outcome	26 weeks
Other	Duration of hospital admission before 'medically fit for discharge'.	Exploratory outcome	26 weeks
Other	Escalation to High Dependency Unit or Intensive Care Unit during primary hospital episode.	Exploratory outcome	26 weeks
Other	Echocardiographic measurements of cardiac function.	Ejection fraction as a percentage	26 weeks
Other	Changes in care, measured by changes in diabetes medication usage.	Exploratory outcome	26 weeks
Primary	Primary outcome: Percent time spent in glucose target range (3.9-10mmol/L)	Percent time spent in glucose target range (3.9-10mmol/L)	26 weeks
Secondary	Number hypoglycaemic excursions.	Number of detected excursions on CGM to glucose <3.9mmol/L	26 weeks
Secondary	Time spent in hypoglycaemia (<3.9mmol/L, 70mg/dL; <3.0mmol/L, 54mg/dL),	Time spent with glucose <3.9mmol/L, time spent with glucose <3mmol/L	26 weeks
Secondary	Time in euglycaemia (3.9-7.8mmol/L, 70-140mg/dL).	Secondary outcome	26 weeks
Secondary	Time in hyperglycaemia (>10mmol/L, 180mg/dL).	Secondary outcome	26 weeks
Secondary	Hypoglycaemia requiring 3rd party assistance.	Number of hypoglycaemia events requiring assistance of 3rd party	26 weeks
Secondary	Number hypoglycaemic excursions (sensor glucose <3.0mmol/l for >= 20min)	Secondary outcome	26 weeks
Secondary	HbA1c at 12 weeks and 26 weeks.	Glycosylated haemoglobin (HbA1c) in percent or mmol/mol	26 weeks
Secondary	Glucose variability assessed by %Coefficient of Variation (%CV).	Variability of glucose (oscillations in glucose values)	26 weeks
Secondary	Mean Absolute Glucose (MAG)	mean absolute Mean absolute glucose change per unit time	26 weeks
Secondary	Health and treatment-related quality of life measured by the Diabetes Treatment Satisfaction Scale score.	The DTSQ s (status version) and DTSQ c (change version) contain eight items each, six of them (questions 1 and 4-8) measure the Treatment Satisfaction and questions 2 and 3, concerning Perceived Frequency of Hyperglycaemia ('Perceived Hyperglycaemia')/Perceived Frequency of Hypoglycaemia ('Perceived Hypoglycaemia') respectively, are treated separately from the satisfaction items and from each other. DTSQs scores range from 6 = very satisfied to 0 = very dissatisfied and DTSQc scores from +3 = much more satisfied now to -3 = much less satisfied now, with 0 (midpoint), representing no change.	26 weeks
Secondary	Hypoglycaemic symptoms	The HypoSRQ is designed to measure the experience of common symptoms associated with hypoglycaemia in people with diabetes. This questionnaire has 18 questions- which require a yes/no response. If the answer is yes, the participant then grades the symptom against 4 categories of severity	26 weeks.
Secondary	Low Blood Glucose Index (LBGI})	Secondary Outcome	26 weeks.
Secondary	Audit of Diabetes Dependent Quality of Life questionnaire domain.	The Audit of Diabetes Dependent Quality of Life -19 questionnaire is a 19 item measure that looks at the impact of diabetes on specific aspects of life and the importance of these aspects for QoL.	26 weeks.